ClinicalTrials.gg
CompletedNCT03358485Updated Aug 15, 2018

Study of Aolanti Weikang Tablets in Healthy Volunteers

A Phase 1 interventional study of Aolanti Weikang tablets and Placebo in Functional Dyspepsia, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 58 studies in Dyspepsia with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Dyspepsia · China.

Enrollment
46th of 46
24 · median 218
Started
2017
with 2 others
Phase 1
Only one
of the 58
Registered
24th of 58
by date
Lead sponsor
2 of 58
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Among the 58 studies in Dyspepsia with a site in China, this one is the 46th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 1, and was the 24th registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

9 of the 58 studies in Dyspepsia with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dyspepsia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses escalation of Aolanti Weikang tablets to determine the MTD in healthy volunteers

Read the detailed description

This is a single-center, randomized, doule blind, placebo-controlled, multiple dose escalaction phase 1b study to evaluate the safety and tolerability of Aolanti Weikang tablets in healthy volunteers. Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD). The proposed dose escalaction levels is 3,6 and 8 tablets. If MTD is not established up to 8 tablets, the dose escalaction will be stopped. In each dose level, subjects will be randomly given orally Aolanti Weikang tablets or placebo tablets at a 3:1 ratio three times a day (tid) for 7 consecutive days, then will receive the Safety follow up for 14 days. No intrapatient dose-escalation is permitted.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) :≥19 and ≤26 kg/m2
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • With in 7 days of Screening, the average number of stool > 2 times/day
  • With in 7 days of Screening, with the presence of ≥ type 5 stool form per the Bristol Stool Form Scale
  • At least one abnormality based the comprehensive examination (including vital signs, physical examination, laboratory examination and others)
  • Digestive diseases, or other diseases within 3 months that may affect the swallow, absorption, or metabolism of study drugs, and not yet fully recovered judged by the Investigator
  • Smoking, alcohol abuse or drug abuse with in 3 months or drinking within 48 hours before the first administration
  • History of drug or aurantium allergy
  • Concomitant medication within 2 weeks prior to drug administration or any drug being used
  • Participated in other clinical trials within 3 months before Screening
  • Major surgery/surgical therapy for any cause within 4 weeks of Screening, or scheduled surgeries within 2 weeks after the last dose of study drug
  • Subjects not agree to use adequate from study entry through at least 28 days after the last dose of study drug
  • Pregnancy or nursing
  • Other conditions that unsuitable for enrollment considered by Investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Aolanti Weikang tablets

    3,6 or 8 Aolanti Weikang tablets each time,tid

    Drug: Aolanti Weikang tablets

  • Placebo comparator
    Placebo

    3,6 or 8 tablets each time,tid

    Other: Placebo

Interventions

  • DrugAolanti Weikang tablets

    Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Maximum-tolerated Dose (MTD) of Aolanti Weikang tablets

    Definition of MTD: the dose level at which 3 or more subjects experienced one or more dose limited toxicities

    Time frame: 3 weeks

Secondary outcomes

  1. Number and grade of treatment-related adverse events (AEs)

    All of the AE are assessed by NCI-CTCAE v4.03

    Time frame: 3 weeks

07

Study locations

1 site
  • Xiyuan Hospital, China Academy of Chinese Medical Sciences
    Beijing, Beijing 100091, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Apr 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Nov 30, 2017
StartActual
Dec 14, 2017
Primary completionActual
Apr 21, 2018
CompletionActual
Jun 30, 2018
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03358485
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Dec 14, 2017
Primary completion
Apr 21, 2018
Completion
Jun 30, 2018
Last update
Aug 15, 2018

Study contacts

Xudong Tang
principal investigator · Xiyuan Hospital of China Academy of Chinese Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion